Nexus Secures Patent Victory for Injectable Cyclophosphamide, Clearing Path for Generic

Nexus Pharmaceuticals has successfully navigated a significant legal hurdle, emerging victorious in a patent litigation concerning its quest to introduce a generic version of injectable cyclophosphamide. On May 9, 2025, the company was granted a favorable judgment in a legal battle against Ingenus Pharmaceuticals, which had accused Nexus of patent infringement.

Cyclophosphamide, a drug approved for treating certain types of cancer, was at the center of this litigation. Nexus Pharmaceuticals aimed to develop a generic version to increase accessibility for patients, a goal now closer to reality following the court's decision. The ruling came from a federal judge in the Northern District of Illinois, who invalidated all claims of Ingenus's patent. The invalidation was based on the term "stable" used within the patent claims, which was deemed indefinite, creating a "zone of uncertainty" that undermined its validity.

The judge concluded that Nexus Pharmaceuticals provided clear and convincing evidence to support their case, leading to a final judgment in their favor. This victory not only allows Nexus to move forward with their plans but also opens the door to broader availability of affordable cancer treatment options. With the patent claims dismissed, Nexus is poised to introduce its generic product to the market, a development welcomed by the company's leadership.

Usman Ahmed, the Chief Executive Officer and President of Nexus Pharmaceuticals, expressed satisfaction with the court's decision. He appreciated the thoroughness of the judicial opinion, which reinforced the invalidity of Ingenus's patent. Ahmed underscored the company's commitment to facilitating patient access to essential medications, emphasizing the positive impact that affordable, generic alternatives can have on healthcare.

Nexus Pharmaceuticals, LLC, is a healthcare company based in the United States, focusing on the development of specialty and generic drugs. The company is renowned for its innovative approaches to drug manufacturing, which aim to simplify usage, reduce labor requirements, and enhance efficiency. Nexus is dedicated to providing high-quality drug products that address unmet medical needs, offering reliable, life-saving treatments precisely when needed.

This legal triumph marks a significant milestone for Nexus Pharmaceuticals, as it reinforces their drive to introduce cost-effective generic medications in the pharmaceutical market. The company's success in this patent litigation is a testament to its strategic vision and commitment to improving patient care through accessible drug options. As Nexus Pharmaceuticals moves forward, its injectable cyclophosphamide product stands to make a meaningful difference in the lives of patients requiring cancer treatment, further solidifying the company's role as a leader in innovative healthcare solutions.